INT279284

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.05
First Reported 2008
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 3
Total Number 3
Disease Relevance 2.22
Pain Relevance 0.04

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (TXK, KDR) nucleus (TXK, KDR) cytoplasm (TXK, KDR)
extracellular region (KDR) cytoplasmic membrane-bounded vesicle (KDR) DNA binding (TXK)
TXK (Homo sapiens)
KDR (Homo sapiens)
Pain Link Frequency Relevance Heat
antagonist 1 85.88 High High
Pain 2 42.72 Quite Low
headache 1 42.24 Quite Low
dexamethasone 16 5.00 Very Low Very Low Very Low
cytokine 8 5.00 Very Low Very Low Very Low
fibrosis 3 5.00 Very Low Very Low Very Low
Potency 2 5.00 Very Low Very Low Very Low
palliative 1 5.00 Very Low Very Low Very Low
Central nervous system 1 5.00 Very Low Very Low Very Low
peripheral neuropathy 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Pancreatic Cancer 69 97.44 Very High Very High Very High
Acute Myeloid Leukemia 22 97.00 Very High Very High Very High
Hematological Disease 1 96.48 Very High Very High Very High
Malignant Neoplastic Disease 10 95.52 Very High Very High Very High
Thrombocytopenia 6 94.44 High High
Hematologic Neoplasms 14 94.00 High High
Myeloid Leukemia 25 90.64 High High
Apoptosis 5 89.32 High High
Cancer 73 85.28 High High
Neuropathic Pain 2 65.36 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Multiple other tyrosine kinase inhibitors targeting the VEGFR, PDGFR, and Src kinases are in various phases of clinical trials testing.
tyrosine kinase Regulation (targeting) of VEGFR
1) Confidence 0.05 Published 2008 Journal Biologics : Targets & Therapy Section Abstract Doc Link PMC2727890 Disease Relevance 0.68 Pain Relevance 0
Small tyrosine kinase inhibitors that target VEGFR are a further important class of anti-angiogenic drugs.
tyrosine kinase Regulation (target) of VEGFR
2) Confidence 0.02 Published 2010 Journal J Angiogenes Res Section Body Doc Link PMC2902424 Disease Relevance 0.63 Pain Relevance 0.04
Small tyrosine kinase inhibitors that target VEGFR are a further important class of antiangiogenic drugs with application to AML, although their efficacy in hemato-lymphoid neoplasias, especially AML, might be attributable to inhibition of a variety of pathways, particularly those related to c-kit and flt3.
tyrosine kinase Regulation (target) of VEGFR associated with acute myeloid leukemia
3) Confidence 0.00 Published 2010 Journal Journal of Oncology Section Body Doc Link PMC2875768 Disease Relevance 0.91 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox